title: The non ergot D2-dopamine agonist CV 205-502 decreases growth hormone concentrations in acromegalic patients.
abstract: It was the aim of this study to test for a possible effect of the new non ergot dopamine agonist CV 205-502 on plasma growth hormone (GH) concentrations in acromegaly. 10 acromegalic patients received a single oral dose of 150 micrograms CV 205-502 after an overnight fast. As a control group 7 acromegalic patients undertook the same procedure without receiving any drug. Blood samples were drawn hourly up to 7 hours thereafter for determination of GH. Plasma growth hormone concentrations decreased by 48.8 +/- 8.7%. The nadir was observed 3 hours after CV 205-502 was administered and GH concentrations remained suppressed throughout the 7 hours of the test period. In contrast GH plasma concentrations in the control group remained stable. We conclude that acute administration of CV 205-502 suppresses GH secretion in acromegalic patients and thus could serve as an alternative therapy in acromegaly.
authors.affiliation: Department of Medicine III, University of Vienna, Austria.
authors.forename: T
authors.initials: T
authors.lastname: Svoboda
authors.forename: H
authors.initials: H
authors.lastname: Kotzmann
authors.forename: M
authors.initials: M
authors.lastname: Clodi
authors.forename: P
authors.initials: P
authors.lastname: Bernecker
authors.forename: G
authors.initials: G
authors.lastname: Geyer
authors.forename: A
authors.initials: A
authors.lastname: Luger
mesh_terms: D000172:Acromegaly / Q000097:blood* / Q000188:drug therapy; D000328:Adult; D000634:Aminoquinolines / Q000494:pharmacology* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged
chemical_list: D000634:Aminoquinolines; D015259:Dopamine Agents; C046650:quinagolide; D013006:Growth Hormone